Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody|[ndash]|drug conjugate SGN-75

摘要

Background:CD70 is an ideal target for antibody-based therapies because of its aberrant high expression in renal carcinomas and non-Hodgkin lymphomas and its highly restricted expression in normal tissues. The expression profiling of CD70 in carcinomas has been limited because of the lack of a CD70-specific reagent that works in formalin-fixed paraffin-embedded (FFPE) tissues.